- /
- Supported exchanges
- / US
- / HAE.NYSE
Haemonetics Corporation (HAE NYSE) stock market data APIs
Haemonetics Corporation Financial Data Overview
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Haemonetics Corporation (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at €19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only €19.99
Get Haemonetics Corporation data using free add-ons & libraries
Get Haemonetics Corporation Fundamental Data
Haemonetics Corporation Fundamental data includes:
- Net Revenue: 1 352 M
- EBITDA: 359 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-06
- EPS/Forecast: 1.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Haemonetics Corporation News
New
Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know
Have you looked into how Haemonetics (HAE) performed internationally during the quarter ending June 2026? Considering the widespread global presence of this provider blood management systems for healt...
HAE Q2 Deep Dive: Plasma and Interventional Growth Drive Outperformance, Margin Outlook Steady
HAE Q2 Deep Dive: Plasma and Interventional Growth Drive Outperformance, Margin Outlook Steady Blood products company Haemonetics (NYSE:HAE) beat Wall Street's revenue expectations in Q2 CY2026, with...
Haemonetics Q1 Earnings Call Highlights
Key Points Interested in Haemonetics Corporation? Here are five stocks we like better. Haemonetics raised its fiscal 2027 outlook, now expecting reported revenue growth of 5%–8% and organic growth ...
Haemonetics Corporation Q1 2027 Earnings Call Summary
Haemonetics Corporation Q1 2027 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and w...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only €19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.